Good evening once again. I'm really glad that I can talk more about Caversoft because
it's really hard to tell you everything in two minutes. So, thank you.
And now I would like to go more scientific.
As I already told you, protein structures are extremely complex and they consist of hundreds
of thousands of atoms basically; and they are long, long chains of amino acids folded
together in a specific shape. And it's really difficult to explore them without proper visualization.
So, the scientists, they look for specific spots inside the protein structure, which is, which
are deeply buried and these sites are called active sides. They are reactive.
And when a ligand, a small molecule, is deployed into the structure to the active
side, a reaction occurs
and some products
are born, and these products are basis of a new medicine or a new chemical
compound of some kind.
So,
n fact, the protein is a factory for our products, and the goal of protein
engineering is to develop the factory.
What we do is detect tunnels
specific pathways inside the protein structure,
so you can imagine it like a mouse drilling holes into a block of cheese.
And we search, of course, for the widest pathways for the, for the shortest pathways.
And there are also a lot of chemical characteristics involved.
So, our software not only enables you to compute these pathways, but it enables you
to evaluate the big data, the big results, immediately and to visualise them.
Now let's move to another level. The proteins are not static structures, they move in
time, they are they are influenced by their surroundings. And you can imagine how it's
hard for the mouse to drill holes there are moving in the cheese. So, what
are the biochemists interested in is, in fact, the stability of these pathways in time,
how they change, if they appear long enough to the ligand
is able to penetrate inside the protein.
These properties you can, you can see, you can evaluate by using various graphs and
teeth plots.
Other, I said,
is that our software is able to process big structures containing of, consisting of thousands,
hundreds of thousands of atoms like this ribosome complex.
Now, let's get some hard data.
Our customers can be divided into two groups. The first is commercial organisations like pharmaceutical
and biotech companies, and also contract research organisations. Then there is the academia.
To get more users attracted to our software, we plan to provide the software for
free. The basic version of our software for free for the noncommercial academia.
Now our revenue will come from a newer licenses, to be able to react to
recent trends in the field, because the development is quite quick.
Of course, we will continue to develop new methods and we will provide our customers
with upgrades.
Very important is to provide scientific support to get the project
customised for specific, for specific research. And to also, when we have the capacity, we
will try to, we will try to develop new analytical methods on demand.
So now, as I said, we have a beta version ready and the first, first
part of next year, we plan to have a commercial product ready And we hope
to have first licenses sold next year,
in the second half.
In the meantime, we will, of course, continue to develop our software, enhance old mentors
and develop new ones.
Now let me briefly introduce our team.
Uur CEOs, we call them bosses, but they are more like advisory board, are professor
Jiri Damborsky and associate professor Jiri Sochor. They are experts in the fields of bioinformatics
and computer science. Then there is six of us.
Researchers and developers. And then there is, wow, he's huge.
Ondrej Valina
who
who will take care of marketing and sales. So, thank you for your attention and
I wish you a pleasant evening.
All right. We tend to go down this path the beginning of each time.
Pricing.
How much does this cost? So, we have been thinking about
a few models, but the basic one is the annual license, which will cost ten
thousand euros.
So you get the software package and you get the support for one year for
ten thousand euros.
But maybe this is a little price for big companies and it's a killing price
for a startup. So, we were also thinking about some
time
time-limited version of our product.
I am... sorry, sorry.
Surprised every time I'm talking to this thing. What is the difference between the free
version and this, and the paying version? Like, why would I buy the ten thousand
euro version, if I can have a free one?
The free one you cannot use when you are performing commercial research. This will be
licensed, so if you are non-commercial academia, you use it for educational purposes, you don't
have to pay for it.
We hope these people, when they later come to... But, I, it's just that I
don't have the rights even though I might do it or is there like an
actual, like
extra... Like, my point is that, you know, I can, you can tell me don't
use it commercially and I might still do it, because
Is there any software difference at all or...? Okay, you won't be able to process
a huge data and you won't be able to evaluate them using those graphs. For
example, useful on the slides. So we really, really cut off version of this software.
Okay, so it's free try-out for small data just to get a hand and then...
Yes. Okay. Yes, you can, you can try the features, you can try everything and
then you are able to buy the full version.
This is great and none of us really understands the area
that you're talking about. But, anyway, maybe you can tell us are you unique in
what you do? Is there any competition? What are they standing for? So, yes, there
is competition in the academia, but these are projects really developed as a part of
some research. Most of them are discontinued and none of them is commercial now.
Moreover, we are the first ones who come up with this solution and iIm proud
to say that we are the most precise. The probability of our analysis is the
highest.
Which is also well published in our, in our articles.
It sounded like you're currently in beta. Do you have any beta testers or...? Yes,
of course.
The first ones we incorporated directly with a protein engineering group here in Brno.
And of course, this group has some friendly research labs,
who will also performe beta testing of our product. So,...
Is there any intellectual property that can be patented?
Well, of course we are thinking about it, but to patent a software its quite
impossible in Czech Republic. So maybe there is some other, other way to do this
by patenting the technology, the algorithms and application of them. So yes, we are thinking
about it, really.
Hi. In your previous presentation, the first one, you mentioned you have already some interested
parties, some interested companies and universities. How many licenses are you hoping to sell next
year then?
That's quite hard to say, but to we hope to sell
ten to twenty licenses
that will be really great.
Thank you for questions.
Hi. I have the last question. You were talking about commercialisation second quarter of 2012,
is it right? First quarter. First quarter of 2013, okay. Because... okay, first quarter is
not that far then. Beause my question is do you need money? Because, you know,
it's something like, it's still far away and you know when you stretch the time
where you actually sell something, sometime you may, you know, you may fall back by
lack of money. So, are you guys on the good path? Do you need money
today? Well, actually we can survive without money
but, as you know,
we can survive, that's the important part. Okay. So if everything goes as planned, we
will have the commercial version in January, February. Okay, it's not too far, fair enough.
So maybe it's good to say that
the testing has to be really precise, the chemists have to cook the protein, test
it if it's relevant, and then publish the results. That's what's important for the big
companies. My last question. Can I just last one... sorry. I mean, if you were
ready in January, do you have people who are really already ready to commit to
buy the product today?
Well, as you saw, these companies, they contacted us directly if we have a commercial
license for them. So we told them to wait until the first quarter, so... Thank
you very much. Thank you for the question.